The Global Market for Pain Management Drugs and Devices
Report Highlights
The global market for pain management will grow from nearly $36.1 billion in 2017 to $52.0 billion by 2022, with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.
Report Includes
- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Examination of product categories, use of products, and the competitive landscape
- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations
- Discussion of new regulatory requirements
- Comprehensive company profiles of major players in the industry
Report Scope
This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study will address acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.
The report identifies two general segments of pain management:
- Pharmaceuticals.
- Devices.
Within the pharmaceuticals segment several sub-segments are discussed in detail including:
- Narcotic pain management.
- Non-narcotic pain management.
- Antimigraine treatments.
- Anesthetics.
- Other drugs (including CNS therapies).
The device segment covers several product lines and specifically targets the largest product segments including:
- Electrotherapy stimulators.
- Spine stimulators.
- Other products (including electromagnetic therapies and other treatments).
Each market segment provides detailed information based on product categories, product use, forecasts and competitive analyses.
Not covered in the report are drugs or devices that by treating the condition or disorder result in the relief of pain. These include treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other similar diseases. Treatments are only included for those that indicate a relief of pain symptoms associated with these conditions.
A comparison of a treatment for the disease that naturally relieves the symptoms as compared to treatments for the relief of pain associated with the disease include:
- Enbrel : Indicated for the treatment of moderate-to-severe rheumatoid arthritis.
- Celebrex : Indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and the management of acute pain.
The report is also evaluated in terms of application, discussing market trends and performance for the following areas:
- Surgical pain.
- Orthopedic/musculoskeletal pain.
- Migraine pain.
- Fibromyalgia pain.
- Cancer pain.
- Neuropathic pain.
- HIV/AIDS pain.
- Dental pain.
- General pain.
Analyst Credentials
Melissa Elder is an experienced healthcare market analyst specializing in medical treatments, equipment and devices. Ms. Elder holds an MBA in Health Care Management and provides consultation to various institutions globally. She has been involved in the healthcare industry since 1996, providing more than 23 years of industry expertise. Ms. Elder has specialized in market research for more than 20 years, focusing on the areas of advanced medical technologies, biological products and animal health. In-depth analysis into more than 100 health-related topics has given Ms. Elder substantial insight into industry dynamics, market influences and future direction of various health markets. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare specialties. She has authored several industry-specific documents and is a well-respected contributor to the market research community. Her writings are published in magazines, newspapers and professional journals. She is also an experienced custom market research writer who has worked with a large variety of clients in many fields who require innumerable variations to research documents.
Report Highlights
Market for global pain management pharmaceuticals and devices by revenue at manufacturers’ sales levels is projected to grow from $36.6 billion in 2014 to nearly $37.8 billion in 2015 and $44.3 billion in 2020, with a compound annual growth rate (CAGR) of 3.2% between 2015 and 2020.
Report Includes
- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
- Analyses of global market trends, with data from 2013 and 2014; estimates for 2015, and projections of CAGRs through 2020.
- Examination of product categories, use of products, and the competitive landscape.
- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
- Discussion of new regulatory requirements.
- Comprehensive company profiles of major players in the industry.
Report Highlights
The market for pain management drugs and devices was valued at $35.4 billion in 2012. Total market valued is expected to reach $41.5 billion in 2017 after increasing at a five-year compound annual growth rate of 3.2%.
Report Includes
- An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
- Analyses of global market trends, with data from 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Examination of product categories, use of products, and the competitive landscape.
- Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
- Discussion of new regulatory requirements.
- Comprehensive company profiles of major players in the industry.
Report Highlights
- The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%.
- The pharmaceuticals segment dominated the market at $17.6 billion in 2008. That figure is expected to increase to $30.2 billion in 2013, for a CAGR of 11.5%.
- The devices segment of the market generated $1.48 billion in sales in 2008 and is projected to increase to $2.5 billion in 2013, for a CAGR of 11.4%.
Report Highlights
-
The global pain-management market is worth around $30.9 billion in 2007. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.63% to reach $40.6 billion by the end of the forecast period, 2012.
-
The pharmaceuticals segment of the pain-management market is valued at $29 billion in 2007. It will be worth $38 billion by 2012 at a CAGR of 5.6%.
-
In 2007, market revenue from the medical devices segment is around $1.9 billion. This segment is predicted to grow at a CAGR of 6.5% to reach $2.6 billion by the end of 2012.
Report Highlights
-
This report presents the forecast of the market for pain management through the year 2005. By 2005, it is anticipated that revenues will likely reach $32 billion, growing at an average annual rate of almost 12%.
-
Pain management pharmaceuticals currently hold the largest market revenue position, representing 97% and accounting for $16 billion of the total in 1999. Pharmaceuticals have long been the mainstay of pain management and it is anticipated that they will remain the largest market share throughout the forecast period.
-
Pain management devices account for 3%, representing $418.5 million in 1999. It is anticipated that the device segment will gain market revenue position due to technological advancements and a gradually declining cost increasing demand for current technologies